Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
sibrotuzumab
National Institutes of Health
Create Alert
Related topics
Related topics
1 relation
Broader (1)
Antibodies, Monoclonal, Humanized
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
Kelsie E. Oatmen
,
E. Cull
,
F. Spinale
Nature Reviews Cardiology
2019
Corpus ID: 207899010
A prolonged state of left ventricular pressure overload, commonly caused by hypertension and aortic valve disease, promotes…
Expand
2017
2017
FBROBLAST ACTIVATION PROTEIN AND MMUNOCONUGATES CONTAINING THEMI
2017
Corpus ID: 55568613
EP O953639 A1 11, 1999 EP 1258255 A1 11, 2002 WO 99.57151 A2 11/1999 WO O1687.08 A2 9, 2001 WO 02083171 10, 2002 WO 2005060999 A2…
Expand
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
,
J. Prous
Methods and findings in experimental and clinical…
2006
Corpus ID: 30340641
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2006
2006
Molecular characterization of sarcomatous change in a granulosa cell tumor
J. Mcneilage
,
M. Alexiadis
,
+5 authors
P. Fuller
International Journal of Gynecologic Cancer
2006
Corpus ID: 25812835
Sarcomatous transformation of a granulosa cell tumor (GCT) is a rare event. We describe the development of a rapidly progressive…
Expand
Highly Cited
2004
Highly Cited
2004
Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients
C. Kloft
,
E-U. Graefe
,
+4 authors
M. Karlsson
Investigational New Drugs
2004
Corpus ID: 24877721
Population pharmacokinetics of sibrotuzumab, a humanized monoclonal antibody directed against fibroblast activation protein, were…
Expand
Highly Cited
2003
Highly Cited
2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
A. Scott
,
G. Wiseman
,
+19 authors
L. Old
Clinical cancer research : an official journal of…
2003
Corpus ID: 15020216
PURPOSE The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor…
Expand
Highly Cited
2003
Highly Cited
2003
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
R. Hofheinz
,
S. Al-Batran
,
+8 authors
G. Stehle
Oncology Research and Treatment
2003
Corpus ID: 29922209
Background: A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein…
Expand
2003
2003
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1
A. Scott
,
G. Wiseman
,
+18 authors
W. Rettig
2003
Corpus ID: 45686630
Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor…
Expand
2003
2003
Cancer Res . , 9 : 1639 Metastatic Fibroblast Activation Protein-positive Cancer . Study of Sibrotuzumab in Patients with Advanced or Dose-EscalationCommentary re : A .
J. Cheng
,
L. Weiner
2003
Corpus ID: 53548123
Highly Cited
2003
Highly Cited
2003
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation…
J. Cheng
,
L. Weiner
Clinical cancer research : an official journal of…
2003
Corpus ID: 43635359
The conventional concept of tumor-host interactions is rooted in the realm of parasitology. A tumor invades an unsuspecting host…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE